Plasma-generated hydroxyl radicals for analysis of three-dimensional structures in protein therapeutics

Ended Project Grant Awarded Last action

Award ID
R44GM134849
Recipient
Awarding agency
Obligated
$3,530,836

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date
Place of performance
Wisconsin, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Immuto scientific INC. Is developing a robust, automated benchtop instrument to perform high-throughput structural characterization of protein biotherapeutics in a fraction of time of traditional structural characterization techniques such as x-RAY crystallography and cryo-EM. Protein-based biotherapeutics (such as antibodies, insulin, recombinant vaccines, etc.) are one of the most effective classes of modern medicines for the treatment of a wide variety of diseases including cancers, autoimmunity/inflammation, genetic disorders, and infectious diseases such as covid-19. The biological function and physicochemical properties of biotherapeutics are determined by their higher order structures (HOS)-the folding and three-dimensional conformation that largely dictates function and stability. Therefore, IT is imperative to analyze the three- dimensional higher order structure of protein therapeutics at several stages of the drug development process to ensure both safety and efficacy of the drug. Biopharmaceutical manufacturers are required to demonstrate the consistency of the protein HOS conformation to the regulatory agencies. Moreover, identifying the binding site of a therapeutic protein (such as a monoclonal antibody) to its corresponding antigen (known as epitope mapping) is critical for the development of new antibody therapeutics, vaccines and diagnostics. Food and drug administration (FDA) guidelines require specific binding site information between a drug and its target for the regulatory filing. Current techniques for protein HOS characterization and epitope mapping are complex, resource intensive and can take up to 6-12 months to perform. Based on feedback received from over 300 customer pharmaceutical customers, we have developed a technology called plasma induced modification to biomolecules (plimb) that addresses the need of the industry for routine structural, mass spectrometry-based protein HOS analysis. Plimb generates sub microsecond bursts of hydroxyl (OH) radicals from water to label proteins in solution. The OH radicals covalently label the solvent accessible regions of the protein and subsequent mass spectrometric analysis reveals single amino acid level structural information. With plimb, HOS analysis and epitope mapping can be performed in under 48 hours where current techniques such as x- RAY crystallography and cryo-EM takes several months to perform. In phase II, we will first incorporate the hydroxyl radical detection system that was designed in phase i into a fully automated, manufacturable plimb instrument, and then validate the plimb system for commercial use. Ultimately, plimb will be a revolutionary new tool for pharmaceutical researchers that will provide new capabilities to better engineer highly effective protein biotherapeutics and accelerate the drug discovery timeline.

Transactions

Action Obligated Date
Amendment $0
Amendment $612,291
Amendment $842,961
Amendment $1,037,792
Original award $1,037,792

Quick answers

Who received award R44GM134849?

R44GM134849 was awarded to Immuto Scientific by National Institute of General Medical Sciences (National Institutes of Health) on September 1, 2019.

How much is award R44GM134849 worth?

$3,530,836 has been obligated on R44GM134849.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login